Saravanan, Rathi http://orcid.org/0000-0002-3884-6023
Holdbrook, Daniel A
Petrlova, Jitka
Singh, Shalini
Berglund, Nils A
Choong, Yeu Khai http://orcid.org/0000-0002-2868-3929
Kjellström, Sven http://orcid.org/0000-0003-4646-5279
Bond, Peter J
Malmsten, Martin
Schmidtchen, Artur http://orcid.org/0000-0001-9209-3141
Funding for this research was provided by:
Lee Kong Chian School of Medicine Postdoctoral Fellowship,Nanyang Technological University, Singapore
Svenska Forskningsrådet Formas (2016-05157, 2012-1883)
LEO Foundation Center for Cutaneous Drug Delivery
Singapore Ministry of Education Academic Research Fund Tier 1
Article History
Received: 2 February 2018
Accepted: 18 June 2018
First Online: 17 July 2018
Competing interests
: A.S. is a founder of in2cure A.B., a company developing therapies based on thrombin-derived host defence peptides. The peptide GKY25 and variants are patent-protected. The remaining authors declare no competing interests.